Lenvatinib combined with immune checkpoint inhibitors for unresectable, recurrent, or metastatic hepatocellular carcinoma: A real-world study
This real-world study supports the possibility of using lenvatinib combined with ICI for the management of patients with unresectable, recurrent, or metastatic HCC, including first-line treatment. Confirmation through a formal clinical trial would provide firmer conclusions.
Authors
- Z. Zeng
- Di Wang (ORCID: https://orcid.org/0000-0003-0870-2157)
- Yu Chen (ORCID: https://orcid.org/0000-0002-1519-4894)
- Xiujuan Chang
- Huifang Kong
- Wei Zhang
- Hong Li
Institutions
- Chinese PLA General Hospital (CN)
- Chinese General Hospital College of Nursing and Liberal Arts (PH)
- Guizhou Provincial People's Hospital (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-03-20
- DOI
- https://doi.org/10.1093/oncolo/oyag097
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00